All you need to know about Cellectis :
4 branchs :
-Oncology
-Sceil
-Cellectis Bioresearch
-Cellectis Plants Science (CPS)
Corporate presentation : urlz.fr/1AWL
http://www.capitalpress.com/Nation_World/Nation/20141125/new-gmo-potato-avoids-usda-regulation
https://www.youtube.com/watch?v=Xj63nYl7h3E
http://sceil.com/
http://www.ascrnetwork.com/index.php?option=com_content&view=article&id=3014:cellectis-bioresearch-inc-wins-a-69-million-contract-with-the-national-institutes-of-health-on-ips-cells&catid=102
http://infocampo.com.ar/nota/campo/67136/cellectis-plant-sciences-una-emergente-que-puede-revolucionar-el-mejoramiento-vegetal
http://www.cellectis.com/en/content/cellectis-step-towards-new-therapy-aids-cellectis-publishes-genome-engineering-advance
http://www.nature.com/srep/2015/150130/srep08150/full/srep08150.html… Read more


Bristol-Myers Squibb ($BMY) picked up FDA approval to use its new oncology treatment in lung cancer, significantly boosting the value of a therapy already expected to bring in billions each year.
The FDA is evaluating proposals for new indications for at least 17 oncology medicines, according to Friends of Cancer Research. The list of therapies includes novel agents and existing drugs whose uses could be expanded if the agency approves the applications.